Literature DB >> 8669175

CA-15.3 assay in effusions: comparison with carcinoembryonic antigen and CA-125 assay and cytologic diagnosis.

M M Pinto1.   

Abstract

OBJECTIVE: To compare the sensitivity of CA-15.3 with cytologic diagnosis and carcinoembryonic antigen (CEA) and CA-125 content and to determine if elevated CA-15.3 suggests a breast primary. STUDY
DESIGN: A retrospective study of 111 consecutive effusions. CEA was measured by enzyme immunoassay (cutoff > 5 ng/mL), CA-125 by radioimmunoassay (cutoff > 5,000 micron/mL) and CA-15.3 by radioimmunoassay (cutoff > 15 micron/mL). Results were correlated with cytologic diagnosis, histology (when available), clinical and radiologic data, and follow-up.
RESULTS: The results were: benign, 39; malignant, 72; sensitivities and specificities: cytology, 76%/100%; CEA, 80%/97%; CA-125 22%/100%; and CA-15.3, 69%/89%. The sensitivity of CEA and cytology was 97% and of CA-15.3 and cytology, 87%. Neither mean (293.4 micron/mL) nor range of CA-15.3 predicted a breast primary. Falsely elevated CEA and CA-15.3 were noted in ascites with fecal contents from colonic perforation. High CA-125 and low CEA predicted an ovarian/endometrial primary.
CONCLUSION: CA-15.3 assay in effusions is not recommended since it neither enhances the sensitivity of cytologic diagnosis nor predicts a breast primary.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8669175     DOI: 10.1159/000333895

Source DB:  PubMed          Journal:  Acta Cytol        ISSN: 0001-5547            Impact factor:   2.319


  3 in total

1.  Value of carcinoembryonic antigen (CEA) and cholesterol assays of ascitic fluid in cases of inconclusive cytology.

Authors:  M Gulyás; A D Kaposi; G Elek; L G Szollár; A Hjerpe
Journal:  J Clin Pathol       Date:  2001-11       Impact factor: 3.411

2.  CA153 in Breast Secretions as a Potential Molecular Marker for Diagnosing Breast Cancer: A Meta Analysis.

Authors:  Shifu Tang; Lili Wei; Yifan Sun; Fang Zhou; Shengbo Zhu; Renqi Yang; Yiyong Huang; Hongyu Zhang; Hong Xu; Jianqing Yang
Journal:  PLoS One       Date:  2016-09-16       Impact factor: 3.240

3.  Evaluation of malignant effusions using MR-based T1 mapping.

Authors:  A Sprinkart; F Kütting; D Kuetting; J Luetkens; A Faron; A Isaak; U Attenberger; C C Pieper; L Meffert; C Jansen
Journal:  Sci Rep       Date:  2021-03-29       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.